EUVIMEDEUVIMED entdecken
Crossref

Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry

ALICE BONAIMÉ, YE (EMMA) WANG

The Journal of Finance · 2024-06 · 79 (3) · 2195-2236

DOI: 10.1111/jofi.13321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Finance, 2024-03. Verfasst von ALICE BONAIMÉ und 1 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Using novel data from the pharmaceutical industry, we study product prices and innovation around mergers. Exploiting within‐deal variation in product market consolidation, we show that prices increase more for drugs in consolidating markets than for matched control drugs. Estimates indicate a 2% average price effect that persists for about one year. Price increases expand with acquirer‐target product similarity and are more pronounced within less competitive product markets with fewer players and no generic competition. Examination of trade‐offs reveals these deals generate significant shareholder value. They also spur labeling and other manufacturing‐related innovation, but not the development of new drugs.

Zitieren

APA

BONAIMÉ, A., & WANG, Y. E. (2024). Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry. The Journal of Finance, 79(3), 2195-2236. https://doi.org/10.1111/jofi.13321

Vancouver

BONAIMÉ A, WANG YE. Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry. The Journal of Finance. 2024;79(3):2195-2236. doi:10.1111/jofi.13321

BibTeX
@article{BONAIM2024,
  author = {BONAIMÉ, ALICE and WANG, YE (EMMA)},
  title = {Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry},
  journal = {The Journal of Finance},
  year = {2024},
  volume = {79},
  number = {3},
  pages = {2195--2236},
  doi = {10.1111/jofi.13321}
}
Kostenlos starten →